Biomm S.A. (BVMF: BIOM3)
10.04
+0.51 (5.35%)
Sep 11, 2024, 4:46 PM GMT-3
Biomm Company Description
Biomm S.A. operates as a biotechnology company in Brazil.
The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA.
Biomm S.A. was founded in 2001 and is headquartered in Nova Lima, Brazil.
Biomm S.A.
Country | Brazil |
Founded | 2001 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 130 |
CEO | Heraldo Marchezini |
Contact Details
Address: 705 – Lagoa dos Ingleses Nova Lima, 34018-000 Brazil | |
Phone | 55 31 3299 1000 |
Website | biomm.com |
Stock Details
Ticker Symbol | BIOM3 |
Exchange | Brazil Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | BRL |
ISIN Number | BRBIOMACNOR2 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Heraldo Carvalho Marchezini | Chief Executive Officer and Member of The Executive Board |
Renato Arroyo Barbeiro | Financial Director, IR and Member of Executive Board |
Francisco Carlos Marques de Freitas | Chief Operating Officer and Member of The Executive Board |
Francisco Rafael Costa Jr. | Commercial Director and Member of Executive Board |
Nayara Rodrigues de Souza Cruz | Accountant |
Mara Bertolin dos Santos Gomes | Controller |